Published in Differentiation on May 20, 2008
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Role for stromal heterogeneity in prostate tumorigenesis. Cancer Res (2011) 1.18
Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia (2012) 0.91
Modeling stromal-epithelial interactions in disease progression. Discov Med (2010) 0.76
Establishment of a syngeneic orthotopic model of prostate cancer in immunocompetent rats. J Toxicol Pathol (2014) 0.75
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15
Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer (2002) 12.45
Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest (2002) 12.22
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. Dev Biol (2001) 10.32
TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23
Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 9.68
Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res (1999) 8.63
Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer (2006) 8.59
Talking about a revolution: The impact of site-specific recombinases on genetic analyses in mice. Dev Cell (2004) 7.06
Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A (2002) 6.98
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis (2002) 6.11
Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest (2004) 5.97
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30
Conditional control of gene expression in the mouse. Nat Rev Genet (2001) 5.30
The logic of TGFbeta signaling. FEBS Lett (2006) 5.26
A receptor for subgroup A Rous sarcoma virus is related to the low density lipoprotein receptor. Cell (1993) 4.97
Genetic manipulation of hedgehog signaling in the endochondral skeleton reveals a direct role in the regulation of chondrocyte proliferation. Development (2001) 4.89
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development (2003) 4.63
Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem (2002) 4.52
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47
Osteo-chondroprogenitor cells are derived from Sox9 expressing precursors. Proc Natl Acad Sci U S A (2005) 4.25
Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20
Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. Dev Dyn (2002) 4.01
Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res (2000) 3.95
Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res (2002) 3.94
Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell (2005) 3.68
A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev (1998) 3.68
Vagaries of conditional gene targeting. Nat Immunol (2007) 3.51
Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell (2002) 3.50
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest (1996) 3.44
The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. Virology (1998) 3.35
Reactive stroma in prostate cancer progression. J Urol (2001) 3.21
The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab Invest (2007) 3.15
Site-specific recombination mediated by an adenovirus vector expressing the Cre recombinase protein: a molecular switch for control of gene expression. J Virol (1995) 3.06
Kinetics of tamoxifen-regulated Cre activity in mice using a cartilage-specific CreER(T) to assay temporal activity windows along the proximodistal limb skeleton. Dev Dyn (2006) 3.05
Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci U S A (2002) 3.03
Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci U S A (1998) 3.00
The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors. Virology (1998) 2.96
Tumor-stroma interactions. Curr Opin Genet Dev (2005) 2.89
Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer (2005) 2.86
Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A (2006) 2.85
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res (1997) 2.80
Molecular biology of bone metastasis. Mol Cancer Ther (2007) 2.71
Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet (2007) 2.54
The possible influence of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice. J Exp Zool (1978) 2.53
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res (2001) 2.51
Malignant transformation in a nontumorigenic human prostatic epithelial cell line. Cancer Res (2001) 2.50
Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp Cell Res (2004) 2.49
Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol (2005) 2.43
Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer (2003) 2.43
Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology (1988) 2.38
Antibodies against macrophages that overlap in specificity with fibroblasts. Kidney Int (2005) 2.34
Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res (2005) 2.32
Development of a smooth muscle-targeted cre recombinase mouse reveals novel insights regarding smooth muscle myosin heavy chain promoter regulation. Circ Res (2000) 2.30
Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A (1987) 2.29
The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol (2002) 2.27
Role of stroma in carcinogenesis of the prostate. Differentiation (2002) 2.26
Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Res (2002) 2.22
Expression and activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissues. Int J Dev Biol (2004) 2.15
Prevalent mutations in prostate cancer. J Cell Biochem (2006) 2.12
Concern Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B). Mol Cell (2002) 2.09
Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol (2003) 2.06
Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res (1997) 2.06
Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase. Nat Biotechnol (2001) 2.05
Multiple organ engraftment by bone-marrow-derived myofibroblasts and fibroblasts in bone-marrow-transplanted mice. Stem Cells (2003) 2.03
Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res (2007) 2.02
Cell differentiation lineage in the prostate. Differentiation (2001) 2.01
Temporally controlled somatic mutagenesis in smooth muscle. Genesis (2000) 2.01
A system for tissue-specific gene targeting: transgenic mice susceptible to subgroup A avian leukosis virus-based retroviral vectors. Proc Natl Acad Sci U S A (1994) 1.99
Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt DNA replication in transgenic fibroblasts. Mol Ther (2001) 1.95
Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene (1999) 1.92
Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate (1999) 1.92
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate (1996) 1.91
Transforming growth factor beta and cell cycle regulation. Cancer Res (1995) 1.84
Retroviral gene delivery. Methods Cell Biol (1997) 1.82
Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol (1989) 1.82
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem (2004) 1.77
Cancer and bone. Endocr Rev (1998) 1.77
Prostatic growth and development are regulated by FGF10. Development (1999) 1.74
c-myc is a downstream target of the Smad pathway. J Biol Chem (2001) 1.74
Stromal-epithelial interactions--I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. J Steroid Biochem (1981) 1.71
Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol (1992) 1.71
Ligand-dependent genetic recombination in fibroblasts : a potentially powerful technique for investigating gene function in fibrosis. Am J Pathol (2002) 1.68
Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol (1999) 1.68
Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology (1991) 1.62
Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts. Int J Cancer (2004) 1.61
Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res (2005) 1.60
Bone marrow derivation of pericryptal myofibroblasts in the mouse and human small intestine and colon. Gut (2002) 1.60
Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci U S A (2006) 1.60
Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate (2005) 1.57
Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res (2005) 1.56
Fibroblast heterogeneity: more than skin deep. J Cell Sci (2004) 1.55
Rapid signalling by androgen receptor in prostate cancer cells. Oncogene (1999) 1.54
Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res (2006) 2.59
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene (2005) 2.35
Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res (2007) 2.02
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res (2008) 1.76
Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest (2012) 1.63
Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res (2011) 1.62
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol (2012) 1.60
Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer. Cancer Res (2005) 1.56
Recruitment of bone marrow derived cells to the bladder after bladder outlet obstruction. J Urol (2009) 1.54
A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells. Eur Urol (2013) 1.51
Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol (2003) 1.46
Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells. Cancer Res (2006) 1.36
Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Cancer Res (2008) 1.36
Transforming growth factor beta-regulated gene expression in a mouse mammary gland epithelial cell line. Breast Cancer Res (2003) 1.32
Understanding the role of stromal fibroblasts in cancer progression. Cell Adh Migr (2012) 1.27
The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach. Cancer Res (2009) 1.21
The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia (2003) 1.20
Identification of extracellular delta-catenin accumulation for prostate cancer detection. Prostate (2009) 1.19
Role for stromal heterogeneity in prostate tumorigenesis. Cancer Res (2011) 1.18
A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells. PLoS One (2008) 1.14
Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. Mol Cancer Res (2012) 1.10
Directed differentiation of embryonic stem cells into bladder tissue. Dev Biol (2007) 1.10
Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression. Cancer Res (2007) 1.08
Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth. PLoS One (2010) 1.07
Dermal transforming growth factor-beta responsiveness mediates wound contraction and epithelial closure. Am J Pathol (2009) 1.05
Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem Biophys Res Commun (2006) 1.05
Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-beta signaling. Differentiation (2008) 1.04
Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One (2011) 1.03
Directed differentiation of bone marrow derived mesenchymal stem cells into bladder urothelium. J Urol (2008) 1.02
Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res (2008) 1.01
Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. PLoS One (2011) 0.99
Role of nicotinic and estrogen signaling during experimental acute and chronic bladder inflammation. Am J Pathol (2007) 0.98
PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia. Differentiation (2011) 0.97
Papillary adenocarcinoma of the renal pelvis and ureter producing carcinoembryonic antigen, carbohydrate antigen 19-9 and carbohydrate antigen 125. Int J Urol (2005) 0.97
Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res (2012) 0.96
Loss of epithelial oestrogen receptor α inhibits oestrogen-stimulated prostate proliferation and squamous metaplasia via in vivo tissue selective knockout models. J Pathol (2011) 0.94
Mesenchymal stem cell recruitment and improved bladder function after bladder outlet obstruction: preliminary data. J Urol (2011) 0.93
Transcriptional profiling of inductive mesenchyme to identify molecules involved in prostate development and disease. Genome Biol (2007) 0.92
A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. PLoS One (2013) 0.92
Bladder tissue formation from cultured bladder urothelium. Dev Dyn (2006) 0.91
Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia (2012) 0.91
Deficiency in metabolic regulators PPARγ and PTEN cooperates to drive keratinizing squamous metaplasia in novel models of human tissue regeneration. Am J Pathol (2012) 0.87
Nicotinic signaling ameliorates acute bladder inflammation induced by protamine sulfate or cyclophosphamide. J Urol (2008) 0.86
Bladder stromal loss of transforming growth factor receptor II decreases fibrosis after bladder obstruction. J Urol (2009) 0.86
Cathepsin D acts as an essential mediator to promote malignancy of benign prostatic epithelium. Prostate (2012) 0.85
Stromal hyperplasia in male bladders upon loss of transforming growth factor-beta signaling in fibroblasts. J Urol (2005) 0.83
A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population. Anticancer Res (2006) 0.81
Down-regulation of Skp2 is correlated with p27-associated cell cycle arrest induced by phenylacetate in human prostate cancer cells. Anticancer Res (2005) 0.81
Temporal-spatial protein expression in bladder tissue derived from embryonic stem cells. J Urol (2008) 0.81
Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma. Int J Urol (2004) 0.81
Reduction of pro-tumorigenic activity of human prostate cancer-associated fibroblasts using Dlk1 or SCUBE1. Dis Model Mech (2012) 0.79
Linking TGF-beta-mediated Cdc25A inhibition and cytoskeletal regulation through RhoA/p160(ROCK) signaling. Cell Cycle (2004) 0.79
Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma. Hinyokika Kiyo (2003) 0.77
Urothelial inhibition of transforming growth factor-beta in a bladder tissue recombination model. J Urol (2007) 0.75